Bill 118 HR 5027, also known as the Chronic Kidney Disease Improvement in Research and Treatment Act of 2023, aims to address the growing issue of chronic kidney disease (CKD) in the United States. The bill focuses on improving research and treatment options for individuals suffering from CKD.
One key aspect of the bill is the establishment of a national CKD registry, which will collect data on patients with CKD to better understand the disease and improve treatment outcomes. This registry will help researchers and healthcare providers identify trends and patterns in CKD, leading to more effective treatment strategies.
Additionally, the bill includes provisions to increase funding for CKD research, with a focus on developing new treatments and therapies for patients. This funding will support clinical trials and research studies aimed at improving outcomes for individuals with CKD.
The bill also addresses the need for increased education and awareness about CKD, particularly in underserved communities. By promoting early detection and prevention efforts, the bill aims to reduce the prevalence of CKD and improve overall public health.
Overall, Bill 118 HR 5027 seeks to enhance research and treatment options for individuals with CKD, with the ultimate goal of improving outcomes and quality of life for those affected by this chronic condition.